The senior vice president of US commercial operations at Amgen (Nasdaq: AMGN) has left to join another US biotech major.
Laura Hamill (pictured above), who oversaw the launch of multiple products across new and existing therapeutic areas at Amgen, is joining Gilead Sciences (Nasdaq: GILD) to become executive vice president for worldwide commercial operations.
"We believe that Laura will help us build on our position of strength in existing therapeutic areas and introduce products in new ones"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze